Chinook Therapeutics, Inc. (KDNY): Price and Financial Metrics
KDNY Price/Volume Stats
| Current price | $40.39 | 52-week high | $40.51 |
| Prev. close | $40.30 | 52-week low | $18.34 |
| Day low | $40.29 | Volume | 4,924,900 |
| Day high | $40.51 | Avg. volume | 1,186,257 |
| 50-day MA | $36.70 | Dividend yield | N/A |
| 200-day MA | $26.37 | Market Cap | 2.90B |
KDNY Stock Price Chart Interactive Chart >
Chinook Therapeutics, Inc. (KDNY) Company Bio
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, an investigational Phase III ready endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates include BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, a preclinical development candidate for an undisclosed ultra-orphan kidney disease, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook Therapeutics, Inc. is based in Seattle, Washington.
KDNY Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | 157.26% |
| 5-year | 647.96% |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | 60.64% |
| 2021 | 2.84% |
| 2020 | 168.81% |
| 2019 | N/A |
Loading social stream, please wait...